Shares of Exact Sciences Corporation fell 4.4% In Tuesday’s post-market trading after the cancer screening and diagnostic tests provider reported lower-than-expected 4Q earnings.
Exact Sciences (EXAS) has pre-announced first quarter results, with total revenue up 114% year-over-year at $348 million, surpassing the Street estimate of $342.6 …
Shares of molecular diagnostics company Exact Sciences (NASDAQ:EXAS) rose by double digits today on heavy volume, thanks to a new U.S.
Rick Wise: High surgeon intrigue in TRXC’s Senhance; Mark Massaro: EXAS could hit 2.7M in tests by 2021.
In a research report published Friday, Canaccord Genuity analyst Mark Massaro reiterated a Buy rating on EXACT Sciences Corporation (NASDAQ:EXAS) and raised the price target …
In a research report issued this morning, Canaccord Genuity analyst Mark Massaro maintained a Buy rating on EXACT Sciences Corporation (NASDAQ:EXAS) with a $27 price …
In a research report released today, Canaccord Genuity analyst Mark Massaro reiterated a Buy rating on Exact Sciences Corporation (NASDAQ:EXAS), and reduced the price target to …
Roth Capital analyst Chris Lewis came out today with an update on Exact Sciences Corp (NASDAQ:EXAS), as the company is in the stage of commercialization of …
In a research note released today, Canaccord analyst Mark Massaro reiterated a Buy rating on Exact Sciences (NASDAQ: EXAS) and raised his price …
In a research note issued today, William Blair analyst Brian Weinstein reiterated an Outperform rating on Exact Sciences Corporation (EXAS) ahead of CMS pricing and miscellaneous data points on early …